Beta Amyloid Peptide is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Beta-amyloid (Aβ) is a 38-43 amino acid peptide derived from the Amyloid Precursor Protein (APP) through sequential proteolytic cleavage by β-secretase and γ-secretase. Aβ is the main component of amyloid plaques in Alzheimer's disease and is central to the amyloid cascade hypothesis.
Amyloidogenic pathway (Aβ-generating):
- β-secretase (BACE1) cleaves at the N-terminus of Aβ → produces sAPPβ + C99
- γ-secretase (presenilin complex) cleaves C99 → releases Aβ peptides (Aβ1-38 to Aβ1-49)
Non-amyloidogenic pathway (alternative):
- α-secretase cleaves within the Aβ domain → produces sAPPα + C83
- γ-secretase cleaves C83 → produces P3 peptide (non-amyloidogenic)
| Species |
Length |
Abundance |
Aggregation |
| Aβ1-38 |
38 aa |
Most abundant |
Less aggregation-prone |
| Aβ1-40 |
40 aa |
80-90% of total |
Forms diffuse plaques |
| Aβ1-42 |
42 aa |
5-10% |
Highly aggregation-prone |
| Aβ1-43 |
43 aa |
Minor |
Most aggregation-prone |
¶ Aggregation and Toxicity
Monomers → Oligomers → Protofibrils → Fibrils → Plaques
Soluble oligomers are considered the most toxic species:
- Aβ oligomers (AβOs): Synaptic dysfunction, memory impairment
- Aβ-derived diffusible ligands (ADDLs): Bind to synapses
- Protofibrils: Intermediate toxic species
- Synaptic dysfunction: Aβ binds to synapses, causes spine loss
- Oxidative stress: Aβ generates reactive oxygen species
- Calcium dyshomeostasis: Aβ forms ion channels in membranes
- Mitochondrial dysfunction: Aβ localizes to mitochondria
- Neuroinflammation: Aβ activates microglia and astrocytes
- Aβ accumulation → 2. Plaque formation → 3. Tau pathology → 4. Neuronal loss → 5. Cognitive decline
Evidence supporting:
- APP/PSEN mutations cause familial AD with increased Aβ production
- APP duplication causes AD-type dementia
- Aβ immunotherapy reduces plaques and may slow decline (in some trials)
Evidence challenging:
- Poor correlation between plaque load and cognitive impairment
- Many elderly have plaques but no dementia
- Anti-Aβ therapies have largely failed to improve cognition
- Aβ1-40 deposits in cerebral blood vessel walls
- Causes hemorrhages, microinfarcts, white matter damage
- Common comorbidity with AD
| Approach |
Example |
Status |
| Active vaccination |
AN1792 (failed), ACI-35 |
Phase 1/2 |
| Monoclonal antibodies |
Aducanumab, Lecanemab, Donanemab |
Approved/Phase 3 |
| Antibody fragments |
Nanobodies |
Preclinical |
| Target |
Strategy |
Status |
| BACE1 inhibitors |
Reduce Aβ production |
Failed (safety) |
| γ-secretase modulators |
Shift to shorter Aβ |
Phase trials |
| α-secretase activators |
Promote non-amyloidogenic |
Preclinical |
- Small molecules to prevent oligomerization
- Peptide inhibitors
- Antibody approaches targeting oligomers
- Structure of Aβ42 fibrils - A. W. Fitzpatrick, 2017
- Aβ oligomer toxicity - S. T. Ferreira, 2015
- Aducanumab approval - S. Budd Haeberlein, 2021
- Lecanemab CLARITY trial - C. H. van Dyck, 2023
The study of Beta Amyloid Peptide has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent studies have advanced our understanding of β-amyloid pathology and therapeutic strategies:
¶ Aβ Heterogeneity and Strains
- Aβ polymorphism: Different Aβ aggregate conformations (polymorphisms) show distinct pathogenicity and may explain clinical variability in AD [1]
- Aβ42/Aβ40 ratio: Alterations in the Aβ42/A40 ratio continue to be studied as predictive biomarkers [2]
- Blood-based biomarkers: Ultra-sensitive plasma assays for Aβ and p-tau show high accuracy for detecting amyloid pathology [3]
- CSF biomarkers: Updates on Aβ42/40 ratio and new candidate markers in cerebrospinal fluid [4]
- Immunotherapy: Lecanemab and donanemab continue to show efficacy in clearing amyloid plaques, with ongoing post-approval studies [5]
- Anti-aggregation drugs: Small molecule inhibitors targeting Aβ aggregation are in various stages of development [6]
- Synaptic toxicity: New insights into how Aβ oligomers disrupt synaptic function [7]
- Metal ion interactions: Role of copper, zinc, and iron in Aβ aggregation and toxicity [8]